Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valagliflozin proglumetac
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Wenzhou Medical University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valagliflozin proglumetac is an investigational potassium-competitive acid blocker (P-CAB) being evaluated for the treatment of reflux esophagitis. It belongs to a class of drugs that inhibit the gastric H+/K+-ATPase (proton pump) by competitively binding to the potassium-binding site, which typically results in faster onset of action and more consistent acid suppression compared to traditional proton pump inhibitors (PPIs). The drug is currently being studied in a real-world multicenter cohort trial in China (ChiCTR2600123809) to assess its efficacy in promoting 8-week esophageal mucosal healing and its overall safety profile in adult patients. The study is sponsored by The First Affiliated Hospital of Wenzhou Medical University.
- Other names
- valagliflozin proglumetac
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on valagliflozin proglumetac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valagliflozin proglumetac.